Fluoxetine Inhibits Hyperresponsive Lamina Propria Mononuclear Cells and Bone Marrow-Derived Dendritic Cells, and Ameliorates Chronic Colitis in IL-10-Deficient Mice

Digestive Diseases and Sciences

Volumn 60, Issue 1, 2015, Pages 101-108

  Koh, Seong Joon ^a   Kim, Ji Won ^a   Kim, Byeong Gwan ^a   Lee, Kook Lae ^a   Im, Jong Pil ^b   Kim, Joo Sung ^b  

^a Seoul National University Boramae Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

Author keywords

Colitis; Dendritic cell; Fluoxetine; IL 10; Inflammatory bowel disease; NF B

Indexed keywords

CYTOKINE; FLUOXETINE; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 12P40; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; TUMOR NECROSIS FACTOR ALPHA; ANTIINFLAMMATORY AGENT; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BODY WEIGHT; BONE MARROW DERIVED DENDRITIC CELL; CELL ISOLATION; COLITIS; COLON; CONTROLLED STUDY; DNA BINDING; ENTERITIS; GEL MOBILITY SHIFT ASSAY; GENE EXPRESSION; INFLAMMATORY BOWEL DISEASE; LAMINA PROPRIA; MALE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PROTEIN SECRETION; REAL TIME POLYMERASE CHAIN REACTION; WILD TYPE; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CHRONIC DISEASE; CYTOLOGY; DENDRITIC CELL; DISEASE MODEL; DRUG EFFECTS; IMMUNOLOGY; INTESTINE MUCOSA; METABOLISM; PATHOLOGY;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BONE MARROW CELLS; CHRONIC DISEASE; COLITIS; CYTOKINES; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; ELECTROPHORETIC MOBILITY SHIFT ASSAY; FLUOXETINE; INTERLEUKIN-10; INTESTINAL MUCOSA; LEUKOCYTES, MONONUCLEAR; MALE; MICE; MICE, INBRED C57BL; NF-KAPPA B;

EID: 84920511005     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-014-3326-9     Document Type: Article

References (29)

1. Baert F, Moortgat L, Van Assche G, et al. Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn’s disease. Gastroenterology. 2010;138:463–468; quiz e410–e461.
2. Ljung T, Karlen P, Schmidt D, et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut. 2004;53:849–853.
3. Sommi RW, Crismon ML, Bowden CL. Fluoxetine: a serotonin-specific, second-generation antidepressant. Pharmacotherapy. 1987;7:1–15.
4. Roumestan C, Michel A, Bichon F, et al. Anti-inflammatory properties of desipramine and fluoxetine. Respir Res. 2007;8:35.
5. Koh SJ, Kim JM, Kim IK, et al. Fluoxetine inhibits NF-kappaB signaling in intestinal epithelial cells and ameliorates experimental colitis and colitis-associated colon cancer in mice. Am J Physiol Gastrointest Liver Physiol.301:G9-19.
6. Becker C, Wirtz S, Blessing M, et al. Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest. 2003;112:693–706.
7. Trinchieri G, Pflanz S, Kastelein RA. The IL-12 family of heterodimeric cytokines: new players in the regulation of T cell responses. Immunity. 2003;19:641–644.
8. MacDonald TT, Monteleone I, Fantini MC, Monteleone G. Regulation of homeostasis and inflammation in the intestine. Gastroenterology. 2011;140:1768–1775.
9. Oppmann B, Lesley R, Blom B, et al. Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12. Immunity. 2000;13:715–725.
10. Bouma G, Strober W. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol. 2003;3:521–533.
11. Trinchieri G. Interleukin-12 and the regulation of innate resistance and adaptive immunity. Nat Rev Immunol. 2003;3:133–146.
12. Hoentjen F, Sartor RB, Ozaki M, Jobin C. STAT3 regulates NF-kappaB recruitment to the IL-12p40 promoter in dendritic cells. Blood. 2005;105:689–696.
13. Karrasch T, Kim JS, Muhlbauer M, Magness ST, Jobin C. Gnotobiotic IL-10−/−;NF-kappa B(EGFP) mice reveal the critical role of TLR/NF-kappa B signaling in commensal bacteria-induced colitis. J Immunol. 2007;178:6522–6532.
14. Rescigno M, Di Sabatino A. Dendritic cells in intestinal homeostasis and disease. J Clin Invest. 2009;119:2441–2450.
15. Berg DJ, Zhang J, Weinstock JV, et al. Rapid development of colitis in NSAID-treated IL-10-deficient mice. Gastroenterology. 2002;123:1527–1542.
16. Weigmann B, Tubbe I, Seidel D, Nicolaev A, Becker C, Neurath MF. Isolation and subsequent analysis of murine lamina propria mononuclear cells from colonic tissue. Nat Protoc. 2007;2:2307–2311.
17. Lee JY, Kim H, Cha MY, et al. Clostridium difficile toxin A promotes dendritic cell maturation and chemokine CXCL2 expression through p38, IKK, and the NF-kappaB signaling pathway. J Mol Med. 2009;87:169–180.
18. Cheon JH, Kim JS, Kim JM, et al. Plant sterol guggulsterone inhibits nuclear factor-kappaB signaling in intestinal epithelial cells by blocking IkappaB kinase and ameliorates acute murine colitis. Inflamm Bowel Dis. 2006;12:1152–1161.
19. Coombes JL, Siddiqui KR, Arancibia-Carcamo CV, et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757–1764.
20. Abdel-Salam OM, Baiuomy AR, Arbid MS. Studies on the anti-inflammatory effect of fluoxetine in the rat. Pharmacol Res. 2004;49:119–131.
21. Davidson NJ, Hudak SA, Lesley RE, Menon S, Leach MW, Rennick DM. IL-12, but not IFN-gamma, plays a major role in sustaining the chronic phase of colitis in IL-10-deficient mice. J Immunol. 1998;161:3143–3149.
22. Trinchieri G. Interleukin-12: a cytokine produced by antigen-presenting cells with immunoregulatory functions in the generation of T-helper cells type 1 and cytotoxic lymphocytes. Blood. 1994;84:4008–4027.
23. Magram J, Connaughton SE, Warrier RR, et al. IL-12-deficient mice are defective in IFN gamma production and type 1 cytokine responses. Immunity. 1996;4:471–481.
24. Sanjabi S, Hoffmann A, Liou HC, Baltimore D, Smale ST. Selective requirement for c-Rel during IL-12 P40 gene induction in macrophages. Proc Natl Acad Sci USA. 2000;97:12705–12710.
25. Murphy TL, Cleveland MG, Kulesza P, Magram J, Murphy KM. Regulation of interleukin 12 p40 expression through an NF-kappa B half-site. Mol Cell Biol. 1995;15:5258–5267.
26. Plevy SE, Gemberling JH, Hsu S, Dorner AJ, Smale ST. Multiple control elements mediate activation of the murine and human interleukin 12 p40 promoters: evidence of functional synergy between C/EBP and Rel proteins. Mol Cell Biol. 1997;17:4572–4588.
27. Jobin C, Sartor RB. The I kappa B/NF-kappa B system: a key determinant of mucosalinflammation and protection. Am J Physiol Cell Physiol. 2000;278:C451–C462.
28. Ardite E, Panes J, Miranda M, et al. Effects of steroid treatment on activation of nuclear factor kappaB in patients with inflammatory bowel disease. Br J Pharmacol. 1998;124:431–433.
29. Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1-stimulated NF-kappaB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem. 1999;274:26448–26453.